WO2012032080A1 - Fc humain stabilisé - Google Patents

Fc humain stabilisé Download PDF

Info

Publication number
WO2012032080A1
WO2012032080A1 PCT/EP2011/065463 EP2011065463W WO2012032080A1 WO 2012032080 A1 WO2012032080 A1 WO 2012032080A1 EP 2011065463 W EP2011065463 W EP 2011065463W WO 2012032080 A1 WO2012032080 A1 WO 2012032080A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding
mutations
antibody
antigen
mutant
Prior art date
Application number
PCT/EP2011/065463
Other languages
English (en)
Inventor
Florian RÜKER
Gordana Wozniak-Knopp
Gottfried Himmler
Luis Serrano
Original Assignee
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H filed Critical F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H
Publication of WO2012032080A1 publication Critical patent/WO2012032080A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the invention refers to a method of preparing a stability engineered human IgG Fc mutant and respective mutants.
  • Monoclonal antibodies have been widely used as therapeutic binding agents.
  • the basic antibody structure will be explained here using as an example an intact lgG1 immunoglobulin.
  • the heavy chains each have four domains.
  • the amino terminal variable domains (VH) are at the tips of the Y.
  • VH amino terminal variable domains
  • IgG, IgD and IgA these are followed by three constant domains: CH1 , CH2, and the carboxy-terminal CH3, at the base of the Y's stem.
  • IgM and IgE there are four different constant domains.
  • a short stretch, the switch connects the heavy chain variable and constant regions.
  • the hinge connects CH2 and CH3 (the Fc fragment) to the
  • the remainder of the antibody (the Fab fragments).
  • One Fc and two identical Fab fragments can be produced by proteolytic cleavage of the hinge in an intact antibody molecule.
  • the light chains are constructed of two domains, variable (VL) and constant (CL), separated by a switch.
  • Disulfide bonds in the hinge region connect the two heavy chains.
  • the light chains are coupled to the heavy chains by additional disulfide bonds.
  • Asn-linked carbohydrate moieties are attached at different positions in constant domains depending on the class of immunoglobulin. For human lgG1 two disulfide bonds in the hinge region, between Cys226 and Cys229 pairs, unite the two heavy chains.
  • the light chains are coupled to the heavy chains by two additional disulfide bonds, between the Cys following Ser221 in the CH1 domain and Cys214 in the CL domain.
  • Carbohydrate moieties are attached to Asn297 of each CH2, generating a pronounced bulge in the stem of the Y. The numbers here are given according to the Kabat numbering scheme.
  • variable regions of both the heavy and light chains (VH) and (VL) lie at the "tips" of the Y, where they are positioned to react with antigen.
  • This tip of the molecule is the side on which the N- terminus of the amino acid sequence is located.
  • the stem of the Y projects in a way to efficiently mediate effector functions such as the activation of complement and interaction with Fc receptors, or ADCC and ADCP. Its CH2 and CH3 domains bulge to facilitate interaction with effector proteins.
  • the C-terminus of the amino acid sequence is located on the opposite side of the tip, which can be termed "bottom" of the Y.
  • lambda Two types of light chain, termed lambda ( ⁇ ) and kappa ( ⁇ ), are found in antibodies.
  • a given immunoglobulin either has kappa chains or lambda chains, never one of each. No functional difference has been found between antibodies having lambda or kappa light chains.
  • Each domain in an antibody molecule has a similar structure of two beta sheets packed tightly against each other in a compressed antiparallel beta barrel. This conserved structure is termed the immunoglobulin fold.
  • the immunoglobulin fold of constant domains contains a 3-stranded sheet packed against a 4-stranded sheet. The fold is stabilised by hydrogen bonding between the beta strands of each sheet, by hydrophobic bonding between residues of opposite sheets in the interior, and by a disulfide bond between the sheets.
  • the 3-stranded sheet comprises strands C, F, and G, and the 4-stranded sheet has strands A, B, E, and D.
  • the letters A through G denote the sequential positions of the beta strands along the amino acid sequence of the immunoglobulin fold.
  • the fold of variable domains has 9 beta strands arranged in two sheets of 4 and 5 strands.
  • the 5-stranded sheet is structurally homologous to the 3-stranded sheet of constant domains, but contains the extra strands C and C".
  • the remainder of the strands (A, B, C, D, E, F, G) have the same topology and similar structure as their counterparts in constant domain immunoglobulin folds.
  • a disulfide bond links strands B and F in opposite sheets, as in constant domains.
  • variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining regions (CDRs).
  • the CDRs are loops that connect beta strands B-C, C'-C", and F-G of the immunoglobulin fold.
  • the residues in the CDRs vary from one immunoglobulin molecule to the next, imparting antigen specificity to each antibody.
  • the VL and VH domains at the tips of antibody molecules are closely packed such that the 6 CDRs (3 on each domain) cooperate in constructing a surface (or cavity) for antigen-specific binding.
  • the natural antigen binding site of an antibody thus is composed of the loops which connect strands B-C, C'-C", and F-G of the light chain variable domain and strands B-C, C'-C", and F-G of the heavy chain variable domain.
  • the loops which are not CDR-loops in a native immunoglobulin, apart from the antigen-binding pocket, which is determined by the CDR loops and optionally adjacent loops within the CDR loop region that contribute to the antigen-binding pocket, do not have antigen binding or epitope binding specificity, but contribute to the correct folding of the entire immunoglobulin molecule, and are therefore called structural loops for the purpose of this invention.
  • the CH3 domain of IgG has been subject to different engineering strategies. With the aim to develop a method for the robust production of bispecific antibodies, Atwell S et al. (J Mol Biol. 1997 Jul 4; 270(1 ):26-35) have developed a heterodimeric CH3 system by mutating residues located in the interface between the two CH3 domains. While the formation of a heterodimer could be shown, the constructs were significantly compromised in stability compared to the wildtype protein.
  • Another reason for mutating a constant domain of an antibody can be to modify its interaction strength with an Fc receptor, as e.g. described by Stavenhagen JB et al. (Adv Enzyme Regul. 2008;48:152-64. Epub 2007 Dec).
  • WO2004035752A2 WO2006053301A2, US20070003546A1 , WO2006076594A2, WO2006105338A2, US20060235208A1 , WO2006053301A2, WO2006076594A2, WO20060201 14A2, WO0042072A2, US20050037000A1 , WO2006088494A2 and WO2004063351A1 .
  • the objective of the invention particularly refers to engineering human lgG1 Fc domains with increased stability, in order to
  • the overall structure of selected binding mutants is as close as possible to the wildtype structure, which represents a superior scaffold to carry mutations in structural loops, leading to engineered binding sites.
  • a method of preparing a stability engineered human IgG Fc mutant by engineering at least one of the point mutations as listed in Table 1 Preferably a combination of such point mutations is employed to enhance the effect of the individual point mutations on thermostability.
  • any such preferred combination of mutations mentioned in the context of the mutations of Table 1 preferably is with each other or with any further mutations.
  • said combination is with one or more of the mutations as listed in Table 2.
  • the method according to the invention comprises engineering at least one of the point mutations as listed in Table 2, i.e. in addition to at least one of the point mutations as listed in Table 1 .
  • Specific embodiments according to the invention refer to the Fc molecule or fragment that comprises at least the exemplified point mutations or combinations of point mutations as listed in Tables 3 or 5.
  • an Fc molecule is engineered to provide a Fc mutant comprising at least one of the mutations selected from the group consisting of:
  • the Fc according to the invention preferably is stability engineered by site directed mutagenesis to incorporate the claimed stabilising mutations.
  • the nucleotide or amino acid sequence is preferably mutated by insertion or substitution.
  • the Fc mutant is selected for its functional scaffold structure as determined by binding to an effector molecule, like CD16a, CD64, FcRn, CD32, C1 q and Protein A.
  • an effector molecule like CD16a, CD64, FcRn, CD32, C1 q and Protein A.
  • the binding to Protein A serves as a surrogate for binding to an effector molecule.
  • the preferred Fc mutant has a Tm value, which is higher than the wild type.
  • Tm value which is higher than the wild type.
  • the increase of any individual Tm value regarding the Fc molecule including T m values of a CH2 and/or CH3 domain, such as T m 1 , T m 2 and/or T m 3, is considered a T m value, which is higher than the wild type.
  • the Fc molecule is further engineered to incorporate a new antigen binding site into the structural loop region, either before engineering the thermostabilising mutations, concomitantly or afterwards.
  • the Fc according to the invention preferably is engineered to incorporate a new antigen binding site by randomisation.
  • the invention refers to stability engineered human IgG Fc mutant having at least one of the point mutations as listed in Table 1 or a combination of such point mutations.
  • the preferred Fc according to the invention comprises a combination with one or more of the mutations as listed in Table 2.
  • a further preferred Fc according to the invention comprises at least one of the mutations as listed in Table 3 or 5.
  • the Fc according to the invention comprises at least one of the mutations selected from the group consisting of:
  • the numbering is according to the Kabat numbering scheme.
  • the Fc according to the invention comprises at least one of the following combinations of point mutations
  • the Fc according to the invention preferably comprises an antigen binding site in the structural loop region.
  • the Fc according to the invention preferably is provided as a single Fc or antigen-binding Fc ("Fcab") or as part of an antibody or Fc construct, such as a full- length antibody or combinations with at least one constant domain and/ or variable domain of an antibody or other binding moieties, such as a receptor. Any kind of binding moiety may be combined with the Fc according to the invention to provide a ligand binding Fc construct.
  • Fcab antigen-binding Fc
  • an antibody or Fc construct such as a full- length antibody or combinations with at least one constant domain and/ or variable domain of an antibody or other binding moieties, such as a receptor.
  • Any kind of binding moiety may be combined with the Fc according to the invention to provide a ligand binding Fc construct.
  • a preferred Fc according to the invention comprises a constant domain contributing to the antigen-binding function of the modular antibody, such as a constant domain which forms at least part of an antigen binding site.
  • an Fc which has a homodimeric structure, e.g. a CH2- CH3 homodimer of polypeptide chains, optionally linked by a hinge region or linker peptide.
  • an Fc library comprising a repertoire of stability engineered Fc mutants according to the invention.
  • the Fc according to the invention is preferably used to provide for a novel scaffold for producing a library of variants, such as antigen-binding variants having different binding properties.
  • the preferred Fc library according to the invention thus comprises Fc variants having different antigen binding properties.
  • the preferred library of Fc variants is mutagenised to obtain a randomised amino acid sequence within a loop region.
  • a preferred method according to the invention provides for mutating a constant domain, which contributes to antigen- binding, such as a constant domain which forms at least part of an antigen binding site.
  • Preferably at least 35% of the Fc variants of such library have a functional scaffold structure as determined by binding to an effector molecule, like CD16a, CD64 and FcRn.
  • thermostabilised or otherwise stabilised mutant of a human IgG Fc is used to engineer an Fc or an Fc library according to the invention. It has proven that at least one of the three observed thermal transitions (T m 1 , T m 2, T m 3) is improved with the Fc according to the invention, as compared to the value obtained with wildtype Fc sequences, irrespective of the existence of an antigen- binding site in the structural loop region or not.
  • intrachain or interchain disulfide bridges may be engineered by mutating a constant domain of the Fc according to the invention to introduce new Cys residues or any other thiol forming amino acid or amino acid analogue to form artificial disulfide bridges.
  • the invention further provides for a method of engineering a constant CH2 and/or CH3 domain by at least one of the point mutations of Table 1 or a combination of such point mutations to increase thermostability of a multidomain modular antibody, specifically when compared to the multidomain modular antibody without such point mutations.
  • the invention further provides for a method of engineering a constant CH2 and/or CH3 domain by at least one of the point mutations of Table 1 or a combination of such point mutations to improve antigen-binding of a multidomain modular antibody, specifically when compared to the multidomain modular antibody without such point mutations.
  • the invention further provides for a method of stability engineering in the framework of a constant domain to increase thermostability and for improving antigen-binding properties of a multidomain modular antibody, which comprises the Fc according to the invention and is composed of at least four antibody domains.
  • Figure 1 shows the sequence of human Fc including the hinge region, numbered by Kabat EU (SEQ ID No. 1 ). Positions of mutation as listed in Tables 1 and 2 are marked bold and underlined)
  • Figure 2 shows the sequence of the CH2 (SEQ ID No. 2) and CH3 (SEQ ID No. 3) domains of human Fc, numbered according to the IMGT. Positions of mutation as listed in Tables 1 and 2 are marked bold and underlined)
  • antigen or "target” as used according to the present invention shall in particular include all antigens and target molecules capable of being recognised by a binding site of an antibody.
  • Specifically preferred antigens as targeted by the Fc according to the invention are those antigens or molecules, which have already been proven to be or are capable of being immunologically or therapeutically relevant, especially those, for which a clinical efficacy has been tested.
  • the term specifically comprises molecules selected from the group consisting of allergens, tumor associated antigens, self antigens including cell surface receptors, enzymes, Fc-receptors, FcRn, HSA, IgG, interleukins or cytokines, proteins of the complement system, transport proteins, serum molecules, bacterial antigens, fungal antigens, protozoan antigen and viral antigens, also molecules responsible for transmissible spongiform encephalitis (TSE), such as prions, infective or not, and markers or molecules that relate to inflammatory conditions, such as pro-inflammatory factors, multiple sclerosis or Alzheimer's disease, or else haptens.
  • TSE transmissible spongiform encephalitis
  • the antigen is either recognized as a whole target molecule or as a fragment of such molecule, especially substructures of targets, generally referred to as epitopes (e.g. B-cell epitopes, T-cell epitopes).
  • epitopes are understood to be immunologically relevant, i.e. are recognisable by natural or monoclonal antibodies. Therefore, the term "epitope” as used herein according to the present invention shall mean a molecular structure which may completely make up a specific binding partner or be part of a specific binding partner to a binding site of an antibody.
  • epitope may also refer to haptens.
  • an epitope may either be composed of a carbohydrate, a peptide, a fatty acid, an organic, biochemical or inorganic substance or derivatives thereof and any combinations thereof. If an epitope is a polypeptide, it will usually include at least 3 amino acids, preferably 8 to 50 amino acids, and more preferably between about 10 to 20 amino acids in the peptide. There is no critical upper limit to the length of the peptide, which could comprise nearly the full length of a polypeptide sequence of a protein. Epitopes can be either linear or conformational epitopes. A linear epitope is comprised of a single segment of a primary sequence of a polypeptide chain. Linear epitopes can be contiguous or overlapping.
  • Conformational epitopes are comprised of amino acids brought together by folding of the polypeptide to form a tertiary structure and the amino acids of the epitope are not necessarily adjacent to one another in the linear sequence.
  • epitopes are at least part of diagnostically relevant molecules, i.e. the absence or presence of an epitope in a sample is qualitatively or quantitatively correlated to either a disease or to the health status of a patient or to a process status in manufacturing or to environmental and food status.
  • Epitopes may also be at least part of therapeutically relevant molecules, i.e. molecules which can be targeted by the specific binding domain which changes the course of the disease.
  • effector molecule as used for the purpose of the invention shall mean a ligand mediating effector functions.
  • exemplary effector ligands are Fc receptors or Fc receptor-like molecules interfering with immunoglobulins.
  • An Fc receptor is a protein found on the surface of certain cells - including natural killer cells, macrophages, neutrophils, and mast cells - that contribute to the protective functions of the immune system.
  • Fc receptors There are several different types of Fc receptors, which are classified based on the type of antibody that they recognize; those that bind the most common class of antibody, IgG, are called Fc-gamma receptors (FcyR).
  • FcyR Fc-gamma receptors
  • Equivalent to an effector ligand and thus incorporated into the definition is any surrogate ligand that recognizes the same or similar binding site within the Fc, such as Protein A.
  • FcyRs includes several members: FcyRI (CD64), FcyRIIA
  • FcRn neonatal Fc receptor
  • effector molecules there are also complement proteins, such as C1 q.
  • complement proteins such as C1 q.
  • the binding to Protein A serves as a surrogate of an effector molecule, Protein A is thus included in the term "effector molecule”.
  • expression system refers to nucleic acid molecules containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed or transfected with these sequences are capable of producing the encoded proteins.
  • the expression system may be included on a vector; however, the relevant DNA may then also be integrated into the host chromosome.
  • an expression system can be used for in vitro transcription/translation .
  • Fc refers to the tail region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system. This property allows antibodies to activate the immune system.
  • the Fc region is composed of two identical protein fragments, derived from the second (CH2) and third (CH3) constant domains of the antibody's two heavy chains.
  • the Fc may be glycosylated or not, depending on the expression system.
  • the term shall include Fc mutants or Fc variants, specifically variants with different antigen- or receptor-binding properties, e.g. antigen binding Fc (Fcab) and Fc constructs.
  • the term Fc shall also include full-length antibodies.
  • the term is understood to include functionally active variants or functional homologues.
  • Fc construct shall mean any molecule comprising an Fc, in particular a full-length antibody or a modular antibody comprising the Fc and other peptides, polypeptides or protein domains, such as a receptor or antigen-binding domain, e.g. an immunoglobulin variable domain, or any other binding moiety.
  • the term "foreign" in the context of amino acids shall mean a newly introduced amino acid in an amino acid sequence, which is usually naturally occurring, but foreign to the site of modification, e.g. by insertion or a substitute of a naturally occurring amino acid.
  • the stabilising point mutations according to the invention typically introduce foreign amino acids.
  • framework region shall refer to those conserved regions of an antibody or antibody domain that are located outside the CDR loop region of an antibody domain including the structural loop regions.
  • the framework region usually comprises or consists of a beta-sheet region of an immunoglobulin domain.
  • the mutations as provided according to the invention are in a framework region, where they do not sterically hinder any antigen-binding site.
  • the framework region of an Fc according to the invention typically is aside from antigen-binding sequences.
  • immunoglobulin as used according to the present invention is defined as polypeptides or proteins that may exhibit mono- or bi- or multi-specific, or mono-, bi- or multivalent binding properties, preferably at least two, more preferred at least three specific binding sites for epitopes of e.g. antigens, effector molecules or proteins either of pathogen origin or of human structure, like self-antigens including cell-associated or serum proteins.
  • immunoglobulin as used according to the invention also includes functional fragments of an antibody, such as Fc, Fab, scFv, single chains of pairs of immunoglobulin domains, like single chain dimers of CH1/CL domains, Fv, or dimers such as VH/VL, CH1/CL, CH2/CH2, CH3/CH3, or other derivatives or combinations of the immunoglobulins.
  • the definition further includes domains of the heavy and light chains of the variable region (such as dAb, Fd, VI, Vk, Vh, VHH) and the constant region or individual domains of an intact antibody such as CH1 , CH2, CH3, CH4, CI and Ck, as well as mini-domains consisting of at least two beta-strands of an immunoglobulin domain connected by a structural loop, or recombined antibody domains, such as strand-exchange engineered domains
  • SEEDbodies like those interdigitating beta-strand segments of human IgG and IgA CH3 domains.
  • the term is understood to include functionally active variants or functional homologues.
  • Module antibodies as used according to the invention are defined as antigen- binding molecules, like antibodies, composed of at least one polypeptide module or protein domain, preferably in the natural form.
  • modular antibodies includes antigen-binding molecules that are either immunoglobulins, fragments thereof or constructs comprising immunoglobulins and other domains exhibiting modular formats and antigen-binding properties similar to immunoglobulins or antibodies, which can be used as antigen-binding scaffolds, preferably based on human proteins.
  • multidomain modular antibody refers to a modular antibody comprising at least two modular antibodies and domains, respectively, preferably at least four antibody domains, e.g. the four domains of an Fc molecule.
  • module antibody include a derivative thereof as well.
  • a derivative is any variant or combination with one or more peptides, polypeptides or protein domains, such as antibody domains and/ or a fusion protein in which any domain or minidomain of the Fc of the invention may be bound or fused at any position with one or more other proteins (such as other modular antibodies, immunoglobulins, ligands, scaffold proteins, enzymes, toxins and the like).
  • a derivative of the Fc of the invention may also be obtained by association or binding to other substances by various chemical techniques such as covalent coupling, electrostatic interaction, disulphide bonding etc.
  • the other substances bound to the Fc may be lipids, carbohydrates, nucleic acids, organic and inorganic molecules or any combination thereof (e.g. PEG, prodrugs or drugs).
  • a derivative would also comprise an Fc with the homologous amino acid sequence, which may contain non-natural or chemically modified amino acids. Further derivatives are provided as fragments of the molecules, containing at least the Fc part of an antibody.
  • Percent (%) amino acid sequence identity with respect to the polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequence and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • point mutations shall refer to a single base
  • substitution wherein a single base nucleotide is replaced with another nucleotide of the genetic material, DNA or RNA.
  • randomisation refers to specific modifications of the nucleic acid or amino acid sequences at predetermined positions, which result from random insertion or exchange or deletion of amino acids, or nucleid acid encoding the exchanged amino acids. Therefore a selection of amino acids or the whole range of natural or synthetic amino acids may be used.
  • the preferred mutagenesis refers to such randomisation techniques, where the amino acid sequence of a peptide or polypeptide is mutated in at least one position, thus a randomised sequence is obtained.
  • “Scaffold” shall mean a temporary framework either natural or artificial used to support the molecular structure of a polypeptide in the construction of variants or a repertoire of the polypeptide. It is usually a modular system of polypeptide domains that maintains the tertiary structure or the function of the parent molecule.
  • Exemplary scaffolds are fragments of modular antibodies, such as Fc, which may be mutagenized to produce variants within said scaffold, to obtain a library.
  • the functional structure of a scaffold is referred to as the "functional scaffold structure”, which can be proven by binding to an effector molecule, e.g. an Fc receptor to an Fc molecule, which is also called scaffold ligand for the purpose of determining the functional scaffold structure.
  • the term “specifically binds” or “specific binding” refers to a binding reaction which is determinative of the cognate ligand of interest in a
  • the antigen-binding Fc according to the invention binds to its particular target and does not bind in a significant amount to other molecules present in a sample.
  • the specific binding means that binding is selective in terms of target identity, high, medium or low binding affinity or avidity, as selected. Selective binding is usually achieved if the binding constant or binding dynamics is at least 10 fold different, preferably the difference is at least 100 fold, and more preferred a least 1000 fold.
  • a "structural loop” or “non-CDR-loop” is to be understood in the following manner: modular antibodies, immunoglobulins or Fc are made of domains with a so called immunoglobulin fold. In essence, antiparallel beta sheets are connected by loops to form a compressed antiparallel beta barrel. Loop regions of constant domains or loop regions of variable domains that are apart from the CDR loop region, i.e. non-CDR loops, are called structural loops. In the variable region, some of the loops of the domains contribute essentially to the specificity of the antibody, i.e. the binding to an antigen by the natural binding site of an antibody. These loops are called CDR-loops.
  • the CDR loops are located within the CDR loop region, which may in some cases also include the variable framework region (called "VFR") adjacent to the CDR loops.
  • VFRs may contribute to the antigen binding pocket of an antibody, which generally is mainly determined by the CDR loops. Thus, those VFRs are considered as part of the CDR loop region, and would not be appropriately used for engineering new additional antigen binding sites. Contrary to those VFRs within the CDR loop region or located proximal to the CDR loops, other VFRs of variable domains would be particularly suitable for engineering an additional antigen binding site.
  • Those are the structural loops of the VFRs located opposite to the CDR loop region, or at the C-terminal side of a variable immunoglobulin domain. Other structural loops are located at the N-terminal or C-terminal side of a constant immunoglobulin domain.
  • the term "variable binding region” sometimes called “CDR region” as used herein refers to varying structures capable of binding interactions with antigens.
  • Molecules with a variable binding region can be used as such or integrated within a larger protein, thus forming a specific region of such protein with binding function.
  • the varying structures can be derived from natural repertoires of binding proteins such as immunoglobulins or receptors.
  • the varying structures can as well be produced by randomisation techniques, in particular those described herein. These include mutagenized CDR or non-CDR regions, loop regions of immunoglobulin variable domains or constant domains.
  • Fc molecules with different modifications at specific sites are also referred to as
  • Variants of a scaffold are preferably grouped to form libraries of binding agents, which can be used for selecting members of the library with predetermined functions.
  • a loop region of a binding agent comprising positions within one or more loops potentially contributing to a binding site, is preferably mutated or modified to produce libraries, preferably by randomisation, such as random, semi-random or, in particular, by site-directed random mutagenesis methods, in particular to delete, exchange or introduce randomly generated inserts into loops, preferably into structural loops.
  • randomisation such as random, semi-random or, in particular, by site-directed random mutagenesis methods, in particular to delete, exchange or introduce randomly generated inserts into loops, preferably into structural loops.
  • site-directed random mutagenesis methods in particular to delete, exchange or introduce randomly generated inserts into loops, preferably into structural loops.
  • combinatorial approaches Any of the known mutagenesis methods may be employed, among them cassette mutagenesis.
  • positions are chosen randomly, e.g. with either any of the possible amino acids or a selection of preferred amino acids to randomise loop sequences, or amino acid changes are made using simplistic rules. For example all residues may be mutated preferably to specific amino acids, such as alanine, referred to as amino acid or alanine scanning. Such methods may be coupled with more sophisticated
  • variants specifically shall refer to functionally active variants.
  • modification of this sequence by insertion, deletion or substitution of one or more amino acids or nucleotides within the sequence or at either or both of the distal ends of the sequence, and which modification does not affect (in particular impair) the activity of this sequence.
  • the functionally active variant of a molecule would still have the predetermined binding specificity, though this could be changed, e.g. to change the fine specificity to a specific epitope, the affinity, the avidity, the Kon or Koff rate, etc.
  • the functionally active variant a) is a biologically active fragment of the molecule, the functionally active fragment comprising at least 50% of the sequence of the molecule, preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95% and most preferably at least 97%, 98% or 99%;
  • b) is derived from the molecule by at least one amino acid substitution, addition and/or deletion, wherein the functionally active variant has a sequence identity to the molecule or part of it, such as a Fc domain, of at least 50%, preferably at least 60%, more preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95% and most preferably at least 97%, 98% or 99%; and/or c) consists of the molecule or a functionally active variant thereof and additionally at least one amino acid or nucleotide heterologous to the polypeptide or the nucleotide sequence, preferably wherein the functionally
  • the functionally active variant may be obtained by sequence alterations in the polypeptide or the nucleotide sequence, wherein the sequence alterations retains a function of the unaltered polypeptide or the nucleotide sequence, when used in combination of the invention.
  • sequence alterations can include, but are not limited to, (conservative) substitutions, additions, deletions, mutations and insertions.
  • the variant of the polypeptide or the nucleotide sequence is functionally active in the context of the present invention, if the activity of the composition of the invention including the variant (but not the original) amounts to at least 10%, preferably at least 25%, more preferably at least 50%, even more preferably at least 70%, still more preferably at least 80%, especially at least 90%, particularly at least 95%, most preferably at least 99% of the activity of the Fc of the invention including the
  • polypeptide or the nucleotide sequence without sequence alteration i.e. the original polypeptide or the nucleotide sequence.
  • the functionally active variant of the Fc according to the invention is essentially identical to the polypeptide or the nucleotide sequence described above, but differs from the polypeptide or the nucleotide sequence, respectively, in that it is derived from a homologous sequence of a different species. These are referred to as naturally occurring variants.
  • an allelic variant also includes naturally occurring allelic variants, as well as mutants or any other non-naturally occurring variants.
  • an allelic variant is an alternate form of a (poly)peptide that is characterized as having a substitution, deletion, or addition of one or more amino acids that does essentially not alter the biological function of the polypeptide.
  • the functionally active variant derived from an Fc molecule according to the invention by amino acid exchanges, deletions or insertions may also conserve, or more preferably improve, the activity or structural stability.
  • Conservative substitutions are those that take place within a family of amino acids that are related in their side chains and chemical properties. Examples of such families are amino acids with basic side chains, with acidic side chains, with non-polar aliphatic side chains, with non-polar aromatic side chains, with uncharged polar side chains, with small side chains, with large side chains etc.
  • polypeptide or the nucleotide sequence as defined above may be modified by a variety of chemical techniques to produce derivatives having essentially the same activity (as defined above for fragments and variants) as the modified modular antibody, and optionally having other desirable properties.
  • G446C 129 it is preferred to combine at least one of the point mutations of Table 1 with each other or with at least one of the point mutations of Table 2, herein called combinatory mutations, to even improve the thermostability.
  • the Fc according to the invention is an immunoglobulin of human origin, and may be employed for various purposes, in particular in pharmaceutical compositions.
  • the Fc according to the invention may also be part of a humanized or chimeric immunoglobulin.
  • a preferred Fc according to the invention which is a human Fc, is derived from immunoglobulin IgG type, specifically preferred lgG1 , lgG2, lgG3 and lgG4 type immunoglobulins or derivatives thereof.
  • the Fc according to the invention is glycosylated. More preferably the glycosylation is a mammalian or plant glycosylation, such as a human, yeast or moss glycosylation, including humanised glycosylation, such as humanised yeast or humanised plant glycosylation.
  • the invention relates to selected point mutations, which have in common the surprisingly increased thermostability of an Fc molecule. It was surprising to find out that a single amino acid substitution would result in a thermostabilised Fc and in the increase of the thermostability as compared to a wildtype Fc. This allows the maintenance of other Fc properties to the best extent, and in particular to use the Fc as a scaffold to provide respective variants, e.g. through mutagenesis within the structural loop region of the Fc.
  • the point mutations of the present invention are preferably introduced aside from an antigen or receptor binding site of the Fc.
  • the biological activity or any antigen-binding property would not be hindered by such stability engineering.
  • An exemplary Fc is characterised in that said at least one framework region comprises at least one of the stabilising mutations besides an antigen-binding region, such as the loop region, which may be part of or comprise a binding site.
  • the framework is mutated to incorporate at least one of the stabilising mutations in such a way, that a binding site could be engineered within the loop region or, if already present, the binding site, represented e.g. by a receptor, peptide or other binding moiety, a CDR loop region or a structural region, would be essentially maintained, e.g. with a loss of affinity (Kd) in binding an antigen, which is not more than 10 "2 M, preferably not more than 10 "1 M.
  • Kd loss of affinity
  • Stability engineering is thus preferred at a position within the framework region of said domain, in particular the beta-sheet region or structural loop regions, which are not used to create an antigen binding site, including loops on the opposite side of the domain as to where the binding site is engineered, such as selected from the group consisting of following amino acid positions:
  • the stabilising mutations of the present invention may be engineered within an antibody domain, e.g. to stabilise the beta-sheet structure, or witin a chain of domains to stabilise the chain or Fc dimer structure (intrachain or interchain stabilisation), to constrain the structure of the Fc according to the invention and support its interaction with potential binding partners.
  • Fc Fc fragment
  • Single mutations and combinations of mutations were introduced by site-directed mutagenesis.
  • the Fc comprising the selected point mutations was prepared by standard molecular biology methods and expressed in a suitable expression system, e.g. in a Pichia pastoris expression system.
  • a suitable expression system e.g. in a Pichia pastoris expression system.
  • expression in CHO cells or in HEK cells is preferred.
  • Mutant proteins were purified from culture supernatants by standard techniques, e.g. using Protein A affinity chromatography.
  • Biophysical analysis included differential scanning calorimetry (DSC), circular dichroism spectrometry (CD) and the verification of the presence of wildtype like effector functions, e.g. by binding to Protein A, CD16a, and FcRn.
  • DSC differential scanning calorimetry
  • CD circular dichroism spectrometry
  • the introduction of the single point mutations e.g. improved the thermal stability of the Fc fragment by 4.5°C.
  • the combination of stabilising mutations even showed a synergistic or at least an additive effect on thermal stability.
  • a shift in the Tm values of the CH2 domain by approx. 9°C and for the CH3 domain by approx. 6°C could be gained by the
  • Stability of the Fc can be analysed by an array of spectroscopic techniques, such as electronic (UV-VIS) spectroscopy, electronic (ECD) and vibrational (VCD) circular dichroism spectroscopy, fluorescence spectroscopy and Fourier Transform Infrared (FTIR) spectroscopy, and by differential scanning calorimetry.
  • spectroscopic techniques such as electronic (UV-VIS) spectroscopy, electronic (ECD) and vibrational (VCD) circular dichroism spectroscopy, fluorescence spectroscopy and Fourier Transform Infrared (FTIR) spectroscopy, and by differential scanning calorimetry.
  • chaotropic agents and/or pH impacts, and/or (iii) interaction of proteins with ligands/binder.
  • the methods are used to study temperature dependent stability and denaturation as well as chemically induced unfolding by urea and guanidinium hydrochloride (GuHCI) and provide important thermodynamic and mechanistic data about domain stability, the pathway of unfolding and the susceptibility of the mutant domains for aggregation.
  • GuHCI guanidinium hydrochloride
  • thermostability was determined by temperature mediated denaturation by DSC.
  • the resulting data included the melting temperature, T m , enthalpy, AH(T m ), and heat capacity increment, AC P , and can be used to determine protein stability function, AG(T).
  • the key assumption of these approaches is that the protein unfolding is (up to a certain point) a thermodynamically reversible (that is, an equilibrium) transition.
  • the stabilising mutation or a combination of such mutation is engineered into an Fc molecule to increase the thermostability value T m 1 and/or T m 2 and/or T m 3 by at least 0,5°C, preferably at least 1 °C, more preferred at least 2°C, at least 3°C, at least 4°C, even more preferred at least 5°C as compared to wildtype Fc.
  • the highest thermostability was obtained with those stabilising mutations that brought about the increase of each of T m 1 , T m 2 and T m 3.
  • the Fc according to the invention could be prepared with a thermal stability of at least 77°C, preferably at least 78°C, more preferably at least
  • thermostability preferably at least 80°C, more preferably at least 81 °C, or at least 82°C, or at least 83°C, or at least 84°C, or at least 85°C, or at least 86°C, or at least 87°C, or at least 88°C, or at least 89°C, or at least 90°C, even more than 90°C, possibly up to 100°C.
  • an antigen binding Fc molecule which usually would have a lower thermostability than the wildtype, a respective increase of thermostability can be shown by the stabilising mutations according to the invention.
  • the heat capacity (or specific heat) of any substance (usually designated Cp at constant pressure) reflects the ability of the substance to absorb heat energy without increase in temperature. At temperatures well below the onset of thermal unfolding, the Cp, excess heat capacity, simply reflects the difference in heat capacity between the protein and the solvent it has displaced. Since water has a high heat capacity compared to most organic substances, including proteins, the apparent Cp in this region will normally be negative. As the protein begins to unfold, the Cp increases as more heat energy is taken up in denaturing the protein, reaching a peak at
  • the calorimetric enthalpy (AHcal) is the total integrated area under the thermogram peak which represents the total heat energy uptake by the sample undergoing the transition. This heat uptake is an absolute measure of the absolute enthalpy of the process.
  • the van't Hoff enthalpy ( ⁇ / ⁇ ) is another estimate of the enthalpy of the transition, based on an assumed model for the process. Here the area under the Cp peak at any temperature, divided by the total area, is used as a measure of the fraction or extent of unfolding that has occurred at that temperature.
  • the van't Hoff enthalpy might differ from the calorimetric enthalpy in protein unfolding. If the unfolding transition is not two-state, but involves one or more intermediate steps, then the transition will appear broader than anticipated, and the ⁇ / ⁇ will be less than AHcal. Alternatively, if the protein unfolds cooperatively as a dimer, or higher oligomer, then the transition will be sharper than anticipated for the two-state transition of a monomer, and the ⁇ / ⁇ will be
  • H enthalpy, or heat content
  • S The absolute entropy (S) is described in terms of "molecular disorder” or the multiplicity of ways in which the molecules in a system can take up energy without increasing temperature.
  • Oligomerization and aggregation of engineered domains can be followed by multi-angle light scattering (MALS) and attenuated total reflectance (ATR) FTIR spectroscopy.
  • MALS allows assessment of molar masses and sizes of the domains in solution and studying of protein interactions in dependence of concentration and physicochemical conditions, e.g. ionic strength.
  • Thermal and chemical denaturation of antibody fragments can be irreversible due to aggregation of the heat-unfolded domains. If protein unfolding and aggregation are concomitant, the unfolding process is inherently irreversible. If aggregation occurs after completion of the unfolding transition, it does not necessarily preclude equilibrium thermodynamic analysis by the spectroscopic techniques described above.
  • ATR-FTIR spectroscopy is a very useful tool to analyse the formation of highly scattering aggregates and to determine their secondary structure. It allows spectral recording of nearly any sample in contact with the surface of the internal reflection element, regardless of transparency. This approach allows the determination and differentiation between different forms of aggregates.
  • Routinely qualitative and quantitative analysis of recombinant antibody domain- glycan is performed by HPLC, MALDI and LC-ESI-MS.
  • mutant Fc molecules according to the invention were designed that contain at least one or combine two, three, or more of these mutations, and the resulting proteins underwent the same analysis and preferred combinatorial mutants were identified.
  • the preferred Fcab libraries will contain a high percentage of well-folded clones, thus increasing the efficiency of identifying high quality binders from the libraries, and finally providing better folded, more stable Fcabs.
  • Such a library derived from a thermostabilised basic scaffold can show a higher proportion of well-folded Fcabs as compared to libraries based on the wildtype Fc scaffold.
  • the number (percentage) of positive clones can be used as a measure for the overall quality of the library members.
  • Those Fc libraries are specifically preferred when at least 35% of the Fc variants have a functional scaffold structure, e.g.
  • Fc variants with different antigen-binding properties can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries, and resulting clones can be selected from these stability-enhanced libraries.
  • the stabilising point mutations could be identified by random mutagenesis and in vitro directed evolution techniques, by applying a high-throughput screening strategy which correlates sequence with structure and stability. Still the outcome of such screening is unforeseeable. It was therefore surprising that the single point mutations as described before were found to be responsible for the increase in thermostability.
  • the Fc according to the invention can be used as isolated Fc or as combination molecules, such as Fc constructs, e.g. through recombination, fusion or conjugation techniques with other peptides or polypeptides.
  • Combinations with peptides, polypeptides and/ or antibody domains are preferably obtained by recombination techniques, but also by binding through adsorption, electrostatic interactions or the like, or else through conjugation or chemical binding with or without a linker.
  • the preferred linker sequence is either a natural linker sequence or functionally suitable artificial sequence.
  • the peptides used for combination purposes are preferably at least 5 amino acids long, more preferably at least 10 or even at least 50 or 100 amino acids long, and preferably constitute at least partially the loop region of an antibody domain.
  • the preferred binding characteristics relate to predefined epitope binding, affinity and avidity.
  • the Fc according to the invention may be used as a building block to molecularly combine other antibody domains or biologically active substances or molecules. It is preferred to molecularly combine at least one antibody binding to the specific partner via the variable or non-variable sequences, like structural loops, with at least one other binding molecule which can be an antibody, antibody fragment, a soluble receptor, a ligand or another antibody domain, or a binding moiety thereof.
  • Other combinations refer to proteinaceous molecules, nucleic acids, lipids, organic molecules and carbohydrates.
  • the preferred format is an Fc, which is homodimeric, e.g. composed of two heavy chains, consisting of CH2-CH3 antibody domains, with or without a covalent bond or a hinge region.
  • the Fc is preferably combined with at least two further antibody domains, more preferred at least 3 or 4 domains, such as to obtain full length antibodies or modular antibodies containing at least the Fc molecule combined with at least one further constant and/or at least one variable domain. Formats based on the combination with at least one pair of modular antibody domains, such as four antibody domains, are particularly preferred.
  • a constant domain is an immunoglobulin fold unit of the constant part of an immunoglobulin molecule, also referred to as a domain of the constant region (e.g. CH1 , CH2, CH3, CH4, Ckappa, Clambda).
  • variable domain is an immunoglobulin fold unit of the variable part of an immunoglobulin, also referred to as a domain of the variable region (e.g. Vh, Vkappa, Vlambda, Vd).
  • the preferred size of the Fc according to the invention is at least 50kD.
  • Fc constructs may have a higher molecular weight, e.g. up to 150kD or even higher, depending on the glycosylation or any additional conjugation of pharmacologically active substances, like toxins or peptides.
  • the Fc according to the invention preferably comprises a binding site to act as a binding agent or binding partner, either as antigen-binding Fc fragment (Fcab) through modifications of the amino acid sequence or as conjugates or fusions to receptors, peptides or other antigen-binding modules.
  • binding agent refers to a member of a binding pair, in particular binding polypeptides having the potential of serving as a binding domain for a binding partner.
  • binding partners include pairs of binding agents with functional interactions, such as receptor binding to ligands, antibody binding to antigen or receptors, a drug binding to a target, and enzyme binding to a substrate.
  • Binding partners are agents that specifically bind to one another, usually through non-covalent interactions.
  • binding partners include pairs of binding agents with functional interactions, such as receptor binding to ligands, antibody binding to antigen, a drug binding to a target, and enzyme binding to a substrate. Binding partners have found use in many therapeutic, diagnostic, analytical and industrial applications. Most prominent binding pairs are antibodies or
  • immunoglobulins fragments or derivatives thereof.
  • binding of such binding agents is required to mediate a biological effect or a function, a "functional interaction".
  • the Fc according to the invention preferably comprises at least one antigen- binding site within the variable and/or the framework region of a variable and/or a constant domain, either formed by respective binding moiteties, such as CDR loops or by randomisation, e.g. within the structural loop region. Binding sites to one or more antigens may be presented by the CDR-region or any other binding structure, or be introduced into a structural loop region of an antibody domain, either of a variable or constant domain structure. Thus, the Fc according to the present invention optionally exerts one or more binding regions to antigens, including binding sites binding specifically to an epitope of an antigen and binding sites potentially mediating effector function.
  • the antigens as used for testing the binding properties of the binding sites may be naturally occurring molecules or chemically synthesized molecules or recombinant molecules, either in solution or in suspension, e.g. located on or in particles such as solid phases, on or in cells or on viral surfaces. It is preferred that the binding of the Fc to an antigen is determined when the antigen is still adhered or bound to molecules and structures in the natural context. Thereby it is possible to identify and obtain those modified modular antibodies that are best suitable for the purpose of diagnostic or therapeutic use.
  • the stabilised modular antibody according to the invention is particularly useful as a scaffold for mutagenesis to introduce new binding sites.
  • error prone PCR is the most frequently used, and numerous protocols and kits are available.
  • the total random approach may be complemented by a semi-random approach, which has been described in the literature as "massive mutagenesis” (Saboulard D et al. Biotechniques. 2005 Sep; 39(3):363-8), and which in essence is site-directed mutagenesis using multiple mutagenic primers simultaneously.
  • a preferred method according to the invention refers to a randomly modified nucleic acid molecule coding for an immunoglobulin, immunoglobulin domain or a part thereof which comprises at least one nucleotide repeating unit within a structural loop coding region having the sequence 5'-NNS-3 ⁇ 5'-NNN-3 ⁇ 5'- NNB-3' or 5'- NNK-3'.
  • the modified nucleic acid comprises nucleotide codons selected from the group of TMT, WMT, BMT, RMC, RMG, MRT, SRC, KMT, RST, YMT, MKC, RSA, RRC, NNK, NNN, NNS or any combination thereof (the coding is according to lUPAC).
  • the modification of the nucleic acid molecule may be performed by introducing synthetic oligonuleotides into a larger segment of nucleic acid or by de novo synthesis of a complete nucleic acid molecule. Synthesis of nucleic acid may be performed with tri-nucleotide building blocks which would reduce the number of nonsense sequence combinations if a subset of amino acids is to be encoded (e.g. Yanez et al. Nucleic Acids Res. (2004) 32:e158; Virnekas et al. Nucleic Acids Res. (1994) 22:5600-5607).
  • the randomly modified nucleic acid molecule may comprise the above identified repeating units, which code for all known naturally occurring amino acids or a subset thereof.
  • Those libraries that contain modified sequences wherein a specific subset of amino acids are used for modification purposes are called “focused” libraries.
  • the member of such libraries have an increased probability of an amino acid of such a subset at the modified position, which is at least two times higher than usual, preferably at least 3 times or even at least 4 times higher.
  • Such libraries have also a limited or lower number of library members, so that the number of actual library members reaches the number of theoretical library members. In some cases the number of library members of a focused library is not less than 10 3 times the theoretical number, preferably not less than 10 2 times, most preferably not less than 10 times.
  • At least one loop region of an Fc which results in a substitution, deletion and/or insertion of one or more nucleotides or amino acids, preferably a point mutation, or even the exchange of whole loops, more preferred the change of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14 or 15, up to 30 amino acids.
  • the modified sequence comprises amino acids not included in the conserved regions of the loops, the newly introduced amino acids being naturally occurring, but foreign to the site of modification, or substitutes of naturally occurring amino acids.
  • the maximum number of amino acids inserted into a loop region of a binding agent preferably may not exceed the number of 30, preferably 25, more preferably 20 amino acids at a maximum.
  • the substitution and the insertion of the amino acids occurs preferably randomly or semi-randomly using all possible amino acids or a selection of preferred amino acids for randomisation purposes, by methods known in the art and as disclosed in the present patent application.
  • the site of modification may be at a specific single loop or a loop region, in particular a structural loop or a structural loop region.
  • a loop region usually is composed of at least two, preferably at least 3 or at least 4 loops that are adjacent to each other, and which may contribute to the binding of an antigen through forming an antigen binding site or antigen binding pocket. It is preferred that the one or more sites of modification are located within the area of 10 amino acids, more preferably within 20, 30, 40, 50, 60, 70, 80, 90 up to 100 amino acids, in particular within a structural region to form a surface or pocket where the antigen can sterically access the loop regions.
  • the preferred modifications are engineered in the loop regions of CH1 , CH2, CH3 and CH4, in particular in the range of amino acids 7 to 21 , amino acids 25 to 39, amino acids 41 to 81 , amino acids 83 to 85, amino acids 89 to 103 and amino acids 106 to 1 17.
  • a modification in the structural loop region comprising amino acids 92 to 98 is combined with a modification in the structural loop region comprising amino acids 8 to 20.
  • the above identified amino acid regions of the respective immunoglobulins comprise loop regions to be modified.
  • a modification in the structural loop region comprising amino acids 92 to 98 is combined with a modification in one or more of the other structural loops.
  • each of the structural loops comprising amino acids 92 to 98, amino acids 41 to 45.2 and amino acids 8 to 20 contain at least one amino acid modification.
  • each of the structural loops comprising amino acids 92 to 98, amino acids 41 to 45.2, and amino acids 8 to 20 contain at least one amino acid modification.
  • amino acid residues in the area of positions 15 to 17, 29 to 34, 41 to 45.2, 84 to 85, 92 to 100, and/or 108 to 1 15 of CH3 are modified.
  • Igk-C and Igl-C of human origin are engineered in the loop regions in the area of amino acids 8 to 20, amino acids 26 to 36, amino acids 41 to 82, amino acids 83 to 88, amino acids 92 to 100, amino acids 107 to 124 and amino acids 123 to 126.
  • loop regions of Igk-C and Igl-C of murine origin are engineered at sites in the area of amino acids 8 to 20, amino acids 26 to 36, amino acids 43 to 79, amino acids 83 to 85, amino acids 90 to 101 , amino acids 108 to 1 16 and amino acids 122 to 126.
  • an immunoglobulin comprising the Fc according to the invention may contain a modification within the variable domain, which is selected from the group of VH, Vkappa, Vlambda, VHH and combinations thereof. More specifically, they comprise at least one modification within amino acids 7 to 22, amino acids 39 to 55, amino acids 66 to 79, amino acids 77 to 89 or amino acids 89 to 104, where the numbering of the amino acid position of the domains is that of the IMGT.
  • the immunoglobulin preferably used is characterised in that the loop regions of VH or Vkappa or Vlambda of human origin comprise at least one modification within amino acids 7 to 22, amino acids 43 to 51 , amino acids 67 to 77, amino acids 77 to 88, and amino acids 89 to 104, most preferably amino acid positions 12 to 17, amino acid positions 45 to 50, amino acid positions 68 to 77, amino acids 79 to 88, and amino acid positions 92 to 99, where the numbering of the amino acid position of the domains is that of the IMGT.
  • the structural loop regions of the variable domain of the immunoglobulin of human origin selected for modification purposes are preferably located in the area of amino acids 8 to 20, amino acids 44 to 50, amino acids 67 to 76, amino acids 78 to 87, and amino acids 89 to 101 .
  • the structural loop regions of the variable domain of the immunoglobulin of murine origin selected for modification purposes are preferably located in the area of amino acids 6 to 20, amino acids 43 to 52, amino acids 67 to 79, amino acids 79 to 87, and amino acids 91 to 100.
  • the Fc according to the invention is particularly useful as a stable scaffold for a library preparation. It is understood that the term “Fc library” always includes libraries of Fc or Fc constructs, fusion proteins, genetic packages or nucleic acids encoding such variants of an Fc or Fc construct, which are understood as members of a library.
  • fusion protein or "chimeric fusion protein” as used for the purpose of the invention shall mean the molecule composed of a genetic package, at least part of an outer surface structure, such as a coat protein, optionally a linker sequence, and a binding agent.
  • the fusion protein is encoded by a vector with the gene of the binding agent and information to display a copy of the binding agent at the surface of the genetic package.
  • each potential binding domain remains physically associated with the particular DNA or RNA molecule which encodes it, and in addition, a the fusion proteins oligomerize at the surface of a genetic package to present the binding polypeptide in the native and functional oligomeric structure.
  • a replicable genetic package such as a virus, cell or spore which replicates and expresses the binding domain-encoding gene, and transports the binding domain to its outer surface.
  • an in-vitro replicable genetic package such as ribosomes that link coding RNA with the translated protein. In ribosome display the genetic material is replicated by enzymatic
  • Those cells or viruses or nucleic acid bearing the binding agents which recognize the target molecule are isolated and, if necessary, amplified.
  • the preferred expression system for the fusion proteins is a non-suppressor host cell, which would be sensitive to a stop codon, such as an amber stop codon, and would thus stop translation thereafter. In the absence of such a stop codon such non-suppressor host cells, preferably E.coli, are preferably used. In the presence of such a stop codon supressor host cells would be used.
  • the vector or plasmid of the genetic package is under tight control of the transcription regulatory element, and the culturing conditions are adjusted so that the amount or number of vector or phagemid particles displaying less than two copies of the fusion protein on the surface of the particle is less than about 20%. More preferably, the amount of vector or phagemid particles displaying less than two copies of the fusion protein is less than 10% the amount of particles displaying one or more copies of the fusion protein. Most preferably the amount is less than 1 %.
  • the expression vector preferably used according to the invention is capable of expressing a binding polypeptide, and may be produced as follows: First a binding polypeptide gene library is synthesized by introducing a plurality of polynucleotides encoding different binding sequences. The plurality of polynucleotides may be synthesized in an appropriate amount to be joined in operable combination into a vector that can be propagated to express a fusion protein of said binding polypeptide. Alternatively the plurality of olynucleotides can also be amplified by polymerase chain reaction to obtain enough material for expression. However, this would only be advantageous if the binding polypeptide would be encoded by a large polynucleotide sequence, e.g. longer than 200 base pairs or sometimes longer than 300 base pairs. Thus, a diverse synthetic library is preferably formed, ready for selecting from said diverse library at least one expression vector capable of producing binding polypeptides having the desired preselected function and binding property, such as specificity.
  • site directed mutagenesis can be employed for generation of the library insert, such as the Kunkel method (Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92) or the Dpnl method (Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC. Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction. Gene. 1994 Dec 30; 151 (1 -2):1 19-23.).
  • Kunkel method Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92
  • Dpnl method Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC. Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction.
  • silent mutations into the sequence encoding the library insert.
  • restriction sites can be introduced which facilitate cloning or modular exchange of parts of the sequence.
  • Another example for the introduction of silent mutations is the ability to "mark" libraries, that means to give them a specific codon at a selected position, allowing them (or selected clones derived from them) e.g. to be recognized during subsequent steps, in which for example different libraries with different characteristics can be mixed together and used as a mixture in the selection procedure.
  • phage display virus display
  • yeast or other eukaryotic cell display such as mammalian or insect cell display
  • mammalian or insect cell display may be used.
  • Mobilized systems are relating to display systems in the soluble form, such as in vitro display systems, among them ribosome display, mRNA display or nucleic acid display.
  • the library is a yeast library and the yeast host cell exhibits at the surface of the cell the Fc and Fc variants.
  • Yeast display offers a number of attractive features: The eukaryotic transcription and translation machinery is very well suited for expression of the Fc, and the use of flow cytometry allows high-throughput quantitative analysis of individual clones in real-time, using scaffold ligands.
  • the yeast host cell is preferably selected from the genera Saccharomyces, Pichia, Hansenula, Schizisaccharomyces, Kluyveromyces, Yarrowia and Candida. Most preferred the host cell is Saccharomyces cerevisiae.
  • the preferred method of producing the Fc according to the invention refers to engineering an Fc that is binding specifically to at least one first epitope and comprising modifications in each of at least two structural loop regions, and determining the specific binding of said at least two loop regions to at least one second epitope, wherein the unmodified structural loop region (non-CDR region) does not specifically bind to said at least one second epitope.
  • an Fc or antigen-binding structure specific for a first antigen may be improved by adding another valency or specificity against a second antigen, which specificity may be identical, either targeting different epitopes or the same epitope, to increase valency or to obtain bi-, oligo- or multispecific molecules.
  • the quality of the Fc library may be proven by the functional scaffold structure.
  • the scaffold ligand can be selected from the group consisting of an effector molecule, FcRn, Protein A, Protein G, Protein L and CDR target.
  • the effector molecule can be selected from the group consisting of CD64, CD32, CD16 and Fc receptors.
  • Libraries according to the invention preferably comprise at least 10 2 library members, more preferred at least 10 3 , more preferred at least 10 4 , more preferred at least 10 5 , more preferred at least 10 6 library members, more preferred at least 10 7 , more preferred at least 10 8 , more preferred at least 10 9 , more preferred at least 10 10 , more preferred at least 10 11 , up to 10 12 members of a library.
  • a pool of preselected independent clones which is e.g. affinity maturated, which pool comprises preferably at least 10, more preferably at least 10 2 , more preferably at least 10 3 , more preferably at least 10 4 , even more than 10 5 independent clones.
  • Those libraries, which contain the pre- selected pools are preferred sources to select the high affinity antigen binding Fc according to the invention.
  • Preferred Fc according to the invention are binding said target antigen with a high affinity, in particular with a high on and/or a low off rate, or a high avidity of binding.
  • a binder is considered a high affinity binder with a Kd of less thanI O "9 M.
  • Medium affinity binders with a Kd of less than 10 "6 M up to 10 "9 M may be provided according to the invention as well, preferably in conjunction with an affinity maturation process.
  • Affinity maturation is the process by which antibodies with increased affinity for antigen are produced. With structural changes of an antibody, including amino acid mutagenesis or as a consequence of somatic mutation in immunoglobulin gene segments, variants of a binding site to an antigen are produced and selected for greater affinities. Affinity matured Fc may exhibit a several logfold greater affinity than a parent antibody. Single parent antibodies may be subject to affinity maturation. Alternatively pools of Fc with similar binding affinity to the target antigen may be considered as parent structures that are varied to obtain affinity matured single antibodies or affinity matured pools of such antibodies.
  • the preferred affinity maturated variant of an Fc according to the invention exhibits at least a 10 fold increase in affinity of binding, preferably at least a 100 fold increase.
  • the affinity maturation may be employed in the course of the selection campaigns employing respective libraries of parent molecules, either with Fc having medium binding affinity to obtain a preferred modular antibody of the invention having a high specific target binding property of a Kd ⁇ 10 "8 M and/or a potency of EC50 ⁇ 10 "8 M.
  • the binding potency or affinity may be even more increased by affinity maturation of the Fc according to the invention to obtain the high values corresponding to a Kd or EC50 of less than 10 "9 M, preferably less than 10 "10 M or even less than 10 "11 M, most preferred in the picomolar range.
  • the EC50 sometimes called IC50, also called 50% saturation concentration, is a measure for the binding potency of a modular antibody. It is the molar concentration of a binder, which produces 50% of the maximum possible binding at equilibrium or under saturation.
  • the potency of an antagonist is usually defined by its IC50 value. This can be calculated for a given antagonist by determining the concentration of antagonist needed to elicit half saturation of the maximum binding of an agonist.
  • Elucidating an IC50 value is useful for comparing the potency of antibodies or antibody variants with similar efficacies; however the dose-response curves produced by both drug antagonists must be similar.
  • affinity of an antibody correlates well with the IC50.
  • the affinity of an antagonist for its binding site (K,), is understood as its ability to bind to a receptor, which determines the duration of binding and respective agonist activity. Measures to increase the affinity by affinity maturation usually also increase the potency of binding, resulting in the respective reduction of IC50 values in the same range of the Kd values.
  • the IC50 and Kd values may be determined using the saturation binding assays well-known in the art.
  • Fc molecules according to the invention that contain native structures interacting with effector molecules or immune cells, thus providing for ADCC, CDC or ADPC. Those native structures either remain unchanged or are preferably modulated for an increased effector function. Binding sites for e.g. Fc receptors are described to be located in a CH2 and/or CH3 domain region, and may be mutagenized by well-known techniques.
  • ADCC antibody-dependent cell-mediated cytotoxicity is the killing of antibody- coated target cells by cells with Fc receptors that recognize the constant region of the bound antibody. Most ADCC is mediated by NK cells that have the Fc receptor
  • FcgammaRIII or CD16 on their surface.
  • Typical assays employ target cells, like Ramos cells, incubated with serially diluted antibody prior to the addition of freshly isolated effector cells. The ADCC assay is then further incubated for several hours and % cytotoxicity detected.
  • Target: Effector ratio is about 1 :16, but may be 1 :1 up to 1 :50.
  • CDC Complement-dependent cytotoxicity
  • the Fc according to the invention preferably has a cytotoxic activity as determined by either of ADCC and CDC assay, preferably in a way to provide a significant increase in the percentage of cytolysis as compared to a control.
  • the absolute percentage increase preferably is higher than 5%, more preferably higher than 10%, even more preferred higher than 20%.
  • the antibody-dependent cellular phagocytosis is usually investigated side by side with cytolysis of cultured human cells.
  • Phagocytosis by phagocytes usually human monocytes or monocyte-derived macrophages, as mediated by an antibody can be determined as follows. Purified monocytes may be cultured with cytokines to enhance expression of FcyRs or to induce differentiation into macrophages.
  • ADCP and ADCC assays are then performed with target cells. Phagocytosis is determined as the percentage of positive cells measured by flow cytometry.
  • the positive ADCP activity is proven with a significant uptake of the antibody-antigen complex by the phagocytes.
  • the absolute percentage preferably is higher than 5%, more preferably higher than 10%, even more preferred higher than 20%.
  • PBMC or monoycytes or monocyte derived macrophages are resuspended in RF2 medium (RPMI 1640 supplemented with 2% FCS) in 96-well plates at a concentration of 1 x 10 5 viable cells in 100 ml/well.
  • Appropriate target cells, expressing the target antigen, e.g. Her2/neu antigen and SKBR3 cells, are stained with PKH2 green fluorescence dye.
  • 1 x 10 4 PKH2-labeled target cells and a test Fc or Fc construct or respective control are added to the well of PBMC's in different concentrations (e.g.
  • PKH2-labeled target cells green are detected in the FL-1 channel (emission wavelength, 530 nm) and RPE-labeled PBMC or monoycytes or monocyte derived macrophages (red) are detected in the FL-2 channel (emission wavelength, 575 nm).
  • Residual target cells are defined as cells that are PKH27RPE "
  • Dual-labeled cells PH27RPE "
  • the Fc according to the invention may specifically bind to any kind of binding molecules or structures, in particular to antigens, proteinaceous molecules, proteins, peptides, polypeptides, nucleic acids, glycans, carbohydrates, lipids, organic molecules, in particular small organic molecules, anorganic molecules, or
  • the preferred Fc according to the invention may comprise at least two loops or loop regions whereby each of the loops or loop regions may specifically bind to different molecules or epitopes.
  • the target antigen is selected from those antigens presented by cells, e.g. cellular targets, like epithelial cells, cells of solid tumors, infected cells, blood cells, antigen-presenting cells and mononuclear cells.
  • cellular targets like epithelial cells, cells of solid tumors, infected cells, blood cells, antigen-presenting cells and mononuclear cells.
  • a target antigen is selected from cell surface antigens, including receptors, in particular from the group consisting of erbB receptor tyrosine kinases (such as EGFR, HER2 including Her2neu, HER3 and HER4, in particular those epitopes of the extracellular domains of such receptors, e.g. the 4D5 epitope).
  • erbB receptor tyrosine kinases such as EGFR, HER2 including Her2neu, HER3 and HER4, in particular those epitopes of the extracellular domains of such receptors, e.g. the 4D5 epitope.
  • further antigens may be targeted, e.g.
  • TNF-receptor super- family molecules of the TNF-receptor super- family, such as Apo-1 receptor, TNFR1 , TNFR2, nerve growth factor receptor NGFR, CD40, CD40-Ligand, OX40, TACI, BCMA, BAFF-receptor, T-cell surface molecules, T- cell receptors, T-cell antigen, Apo-3, DR4, DR5, DR6, decoy receptors, such as DcR1 , DcR2, CAR1 , HVEM, GITR, ZTNFR-5, NTR-1 , TNFL1 , IGFR-1 , c-Met, but not limited to these molecules, B-cell surface antigens, such as CD10, CD19, CD20, CD21 , CD22, DC-SIGN, antigens or markers of solid tumors or hematologic cancer cells, cells of lymphoma or leukaemia, other blood cells including blood platelets, but not limited to these molecules.
  • a target antigen is selected from those antigens presented by cells, like epithelial cells or cells of solid tumors.
  • Those target antigens expressed or overexpressed by cells are preferably targeted, which are selected from the group consisting of tumor associated antigens, in particular EpCAM, tumor-associated glycoprotein-72 (TAG-72), tumor-associated antigen CA 125, Prostate specific membrane antigen (PSMA), High molecular weight melanoma- associated antigen (HMW-MAA), tumor-associated antigen expressing Lewis y related carbohydrate, Carcinoembryonic antigen (CEA), CEACAM5, HMFG PEM, mucin MUC1 , MUC18 and cytokeratin tumor-associated antigen, CD44 and its splice variants, bacterial antigens, viral antigens, allergens, allergy related molecules IgE, cKIT and Fc-epsilon-receptor I, IRp60, IL-5 receptor, CCR3, red blood cell
  • TNFbeta2 TNFalpha, TNFalphabeta, TNF-R1 , TNF-RII, FasL, CD27L, CD30L, 4- 1 BBL, TRAIL, RANKL, TWEAK, APRIL, BAFF, LIGHT, VEG1 , OX40L, TRAIL
  • Receptor-1 A1 Adenosine Receptor, Lymphotoxin Beta Receptor, TACI, BAFF-R, EPO; LFA-3, ICAM-1 , ICAM-3, integrin betal , integrin beta2, integrin alpha4/beta7, integrin alpha2, integrin alpha3, integrin alpha4, integrin alpha5, integrin alpha6, integrin alphav, alphaVbeta3 integrin, FGFR-3, Keratinocyte Growth Factor, GM-CSF, M-CSF, RANKL, VLA-1 , VLA-4, L-selectin, anti-Id, E-selectin, HLA, HLA-DR, CTLA-4, T cell receptor, B7-1 , B7-2, VNRintegrin, TGFbetal , TGFbeta2, eotaxinl , BLyS (B- lymphocyte Stimulator), complement C5, IgE, IgA
  • HCMV human cytomegalovirus
  • RSV respiratory syncytial virus
  • RSVF ribosomal virus
  • VNRintegrin Hep B gp120, CMV, gpllbllla, HIV NIB gp120 V3 loop
  • RSV respiratory syncytial virus
  • HSV Herpes simplex virus
  • HSV Herpes simplex virus
  • the Fc according to the invention is preferably conjugated to a label or reporter molecule, selected from the group consisting of organic molecules, enzyme labels, radioactive labels, colored labels, fluorescent labels, chromogenic labels, luminescent labels, haptens, digoxigenin, biotin, metal complexes, metals, colloidal gold and mixtures thereof.
  • a label or reporter molecule selected from the group consisting of organic molecules, enzyme labels, radioactive labels, colored labels, fluorescent labels, chromogenic labels, luminescent labels, haptens, digoxigenin, biotin, metal complexes, metals, colloidal gold and mixtures thereof.
  • Modified Fc conjugated to labels or reporter molecules may be used, for instance, in assay systems or diagnostic methods.
  • the Fc according to the invention may be conjugated to other molecules which allow the simple detection of said conjugate in, for instance, binding assays (e.g.
  • Fc variants are screened using one or more cell-based or in vivo assays.
  • purified or unpurified modified Fc are typically added exogenously such that cells are exposed to individual Fc or pools of Fc belonging to a library.
  • These assays are typically, but not always, based on the function of the immunoglobulin; that is, the ability of the antibody to bind to its target and mediate some biochemical event, for example effector function, ligand/receptor binding inhibition, apoptosis, and the like.
  • Such assays often involve monitoring the response of cells to the antibody, for example cell survival, cell death, change in cellular morphology, or transcriptional activation such as cellular expression of a natural gene or reporter gene.
  • such assays may measure the ability of Fc variants to elicit ADCC, ADCP, or CDC.
  • additional cells or components, that is in addition to the target cells may need to be added, for example example serum complement, or effector cells such as peripheral blood monocytes
  • PBMCs PBMCs
  • NK cells NK cells
  • macrophages and the like.
  • additional cells may be from any organism, preferably humans, mice, rat, rabbit, and monkey.
  • Fc molecules may cause apoptosis of certain cell lines expressing the target, or they may mediate attack on target cells by immune cells which have been added to the assay.
  • Methods for monitoring cell death or viability are known in the art, and include the use of dyes, immunochemical, cytochemical, and radioactive reagents.
  • caspase staining assays may enable apoptosis to be measured, and uptake or release of radioactive substrates or fluorescent dyes such as alamar blue may enable cell growth or activation to be monitored.
  • the DELFIART EuTDA-based cytotoxicity assay (Perkin Elmer, MA) may be used.
  • dead or damaged target cells may be monitored by measuring the release of one or more natural intracellular components, for example lactate dehydrogenase.
  • Transcriptional activation may also serve as a method for assaying function in cell-based assays.
  • response may be monitored by assaying for natural genes or immunoglobulins which may be upregulated, for example the release of certain interleukins may be measured, or alternatively readout may be via a reporter construct.
  • Cell-based assays may also involve the measure of morphological changes of cells as a response to the presence of an Fc according to the invention.
  • Cell types for such assays may be prokaryotic or eukaryotic, and a variety of cell lines that are known in the art may be employed.
  • cell-based screens are performed using cells that have been transformed or transfected with nucleic acids encoding the variants.
  • the cell-based screen utilizes cell surface display.
  • a fusion partner can be employed that enables display of modified Fc on the surface of cells (Wittrup, 2001 , Curr Opin Biotechnol, 12:395-399).
  • the Fc of the invention is preferably provided as a recombinant protein expressed by a host cell, e.g. by expression in the periplasmic space of E. coli or by expression as a secreted protein in a eukaryotic expression system such as yeast or mammalian, e.g. by CHO, HEK or human production host cell lines.
  • a host cell e.g. by expression in the periplasmic space of E. coli or by expression as a secreted protein in a eukaryotic expression system such as yeast or mammalian, e.g. by CHO, HEK or human production host cell lines.
  • the immunogenicity of the Fc according to the invention may be determined experimentally using one or more cell-based assays.
  • ex vivo T-cell activation assays are used to experimentally quantitate immunogenicity.
  • antigen presenting cells and naive T cells from matched donors are challenged with an Fc of interest one or more times.
  • T cell activation can be detected using a number of methods, for example by monitoring production of cytokines or measuring uptake of tritiated thymidine.
  • interferon gamma production is monitored using Elispot assays.
  • the biological properties of the Fc according to the invention may be any biological properties of the Fc according to the invention.
  • drugs are often tested in vivo in animals, including but not limited to mice, rats, rabbits, dogs, cats, pigs, and monkeys, in order to measure a drug's efficacy for treatment against a disease or disease model, or to measure a drug's pharmacokinetics, pharmacodynamics, toxicity, and other properties.
  • the animals may be referred to as disease models.
  • Therapeutics are often tested in mice, including but not limited to nude mice, SCID mice, xenograft mice, and transgenic mice (including knockins and knockouts).
  • Such experimentation may provide meaningful data for determination of the potential of the antibody to be used as a therapeutic with the appropriate half-life, effector function, apoptotic activity, cytotoxic or cytolytic activity.
  • Any organism preferably mammals, may be used for testing.
  • primates, monkeys can be suitable therapeutic models, and thus may be used to test the efficacy, toxicity, pharmacokinetics, pharmacodynamics, half-life, or other property of the modular antibody according to the invention. Tests of the substances in humans are ultimately required for approval as drugs, and thus of course these experiments are contemplated.
  • the Fc of the present invention may be tested in humans to determine their therapeutic efficacy, toxicity, immunogenicity, pharmacokinetics, and/or other clinical properties.
  • those Fc variants according to the invention that bind to single cell or a cellular complex through at least two binding motifs, preferably binding of at least three structures cross-linking target cells, would be considered effective in effector activity or preapoptotic or apoptotic activity upon cell targeting and cross-linking.
  • Multivalent binding provides a relatively large association of binding partners, also called cross- linking, which is a prerequisite for apoptosis and cell death.
  • the Fc of the present invention may find use in a wide range of antibody products.
  • the Fc of the present invention is used for therapy or prophylaxis, e.g. as an active or passive immunotherapy, for preparative, industrial or analytic use, as a diagnostic, an industrial compound or a research reagent, preferably a therapeutic.
  • the Fc may specifically find use in an antibody composition that is monoclonal or polyclonal.
  • the Fc of the present invention is used to capture or kill target cells that bear the target antigen, for example cancer cells.
  • the Fc of the present invention is used to block, antagonize, or agonize the target antigen, for example by antagonizing a cytokine or cytokine receptor.
  • the Fc of the present invention is used to block, antagonize, or agonize growth factors or growth factor receptors and thereby mediate killing the target cells that bear or need the target antigen.
  • the Fc of the present invention is used to block, antagonize, or agonize enzymes and substrate of enzymes.
  • a Fc of the present invention is administered to a patient to treat a specific disorder.
  • a "patient” for the purposes of the present invention includes both humans and other animals, preferably mammals and most preferably humans.
  • specific disorder herein is meant a disorder that may be ameliorated by the administration of a pharmaceutical composition comprising an Fc of the present invention.
  • an Fc according to the present invention is the only therapeutically active agent administered to a patient.
  • the Fc according the present invention is administered in combination with one or more other therapeutic agents, including but not limited to cytotoxic agents, chemotherapeutic agents, cytokines, growth inhibitory agents, anti-hormonal agents, kinase inhibitors, anti- angiogenic agents, cardioprotectants, or other therapeutic agents.
  • the Fc may be administered concomitantly with one or more other therapeutic regimens.
  • an Fc of the present invention may be administered to the patient along with chemotherapy, radiation therapy, or both chemotherapy and radiation therapy.
  • the Fc of the present invention may be administered in conjunction with one or more antibodies.
  • the Fc of the present invention and one or more other anti-cancer therapies is employed to treat cancer cells ex vivo. It is contemplated that such ex vivo treatment may be useful in bone marrow transplantation and particularly, autologous bone marrow
  • the Fc of the invention can be employed in combination with still other therapeutic techniques such as surgery.
  • a variety of other therapeutic agents may find use for administration with the Fc of the present invention.
  • the Fc is administered with an anti- angiogenic agent, which is a compound that blocks, or interferes to some degree, the development of blood vessels.
  • the anti-angiogenic factor may, for instance, be a small molecule or a protein, for example an antibody, Fc fusion molecule, or cytokine, that binds to a growth factor or growth factor receptor involved in promoting angiogenesis.
  • the preferred anti-angiogenic factor herein is an antibody that binds to Vascular Endothelial Growth Factor (VEGF).
  • VEGF Vascular Endothelial Growth Factor
  • the Fc is administered with a therapeutic agent that induces or enhances adaptive immune response, for example an antibody that targets CTLA-4.
  • the Fc is administered with a tyrosine kinase inhibitor, which is a molecule that inhibits to some extent tyrosine kinase activity of a tyrosine kinase.
  • the Fc of the present invention is administered with a cytokine.
  • cytokine as used herein is meant a generic term for proteins released by one cell population that act on another cell as intercellular mediators including chemokines.
  • compositions are contemplated wherein the Fc of the present invention and one or more therapeutically active agents are formulated.
  • Stable formulations of the Fc of the present invention are prepared for storage by mixing said Fc having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilisers, in the form of lyophilized formulations or aqueous solutions.
  • the formulations to be used for in vivo administration are typically sterile. This is readily accomplished by filtration through sterile filtration membranes or other methods.
  • the Fc and other therapeutically active agents disclosed herein may also be formulated as immunoliposomes, and/or entrapped in microcapsules.
  • Administration of the pharmaceutical composition comprising an Fc of the present invention may be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, intraotically, transdermal ⁇ , mucosal, topically (e.g., gels, salves, lotions, creams, etc.), intraperitoneally, intramuscularly, intrapulmonary (e.g., AERxTM inhalable technology commercially available from Aradigm, or InhanceTM pulmonary delivery system commercially available from Inhale Therapeutics), vaginally, parenterally, rectally, or intraocularly.
  • AERxTM inhalable technology commercially available from Aradigm
  • InhanceTM pulmonary delivery system commercially available from Inhale Therapeutics
  • vaginally parenterally, rectally, or intraocularly.
  • Method according to definition 1 which further comprises engineering at least one of the point mutations as listed in Table 2.
  • Fc according to definition 9 which further comprises at least one of the point mutations as listed in Table 2.
  • Fc according to definition 9 or 10, comprising at least one of the mutations as listed in Table 3 or 5.
  • Fc according to definition 9 or 10 comprising at least one of the mutations selected from the group consisting of:
  • Fc according to any of definitions 9 to 10, comprising at least one of the combination of point mutations selected from the group consisting of:
  • Fc according to any of definitions 9 to 13, comprising an antigen binding site in the structural loop region.
  • Fc library comprising a repertoire of stability engineered Fc mutants according to any of definitions 9 to 14.
  • thermostabilised mutant of a human IgG Fc to engineer an Fc library.
  • point mutations as listed in Table 1 and combinatory mutations that combine at least one of the point mutations of Table 1 with each other or with at least one of the point mutations of Table 2 were designed.
  • pPICZalphaA The gene coding for wildtype Fc of human lgG1 , starting with amino acid residue 225 (Kabat EU index numbering) and ending with amino acid residue 447 (see for example GenBank entry BAC86226.1 ) was cloned into the Pichia pastoris expression vector pPICZalphaA (Invitrogen, Carlsbad, CA). This vector allows highlevel, methanol inducible expression of the gene of interest in Pichia, and can be used in various Pichia strains including X-33 and GS1 15.
  • pPICZalphaA contains, amongst other elements, a 5' fragment containing the AOX1 promoter for tightly regulated, methanol-induced expression of the gene of interest, the 3' AOX1
  • the genes coding for the mutant Fc proteins were prepared by site directed mutagenesis of the gene coding for wildtype Fc using standard procedures.
  • the QuikChange Site Directed Mutagenesis Kit or the QuikChange Multi Site Directed Mutagenesis Kit were used according to the instructions provided by the manufacturer. The mutant sequences were verified by DNA
  • ⁇ is the actual heat absorption during protein unfolding, whereas ⁇ is the theoretical heat of the transition assuming a two-state model.
  • Table 3 describes the mutations within the amino acid sequence of human lgG1 Fc (Fc wild- type). The constructs comprising point mutations in the CH2 and/or CH3 domains are given and the thermostabilising effect as measured by an increase of any individual Tm value is shown, when compared to the respective Tm value of the wild-type sequence.
  • H 10-03-6 is an Fcab that binds specifically and with high affinity to HER2/neu via a binding site that has been engineered in structural loops of the CH3 domain (Wozniak-Knopp et al.: Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel. 2010 Apr;23 (4):289-97. Epub 2010 Feb 1 1 . PubMed PMID: 20150180). Relative to wildtype Fc, H10-03-6 displays reduced thermostability, with a T m 1 of 61 ,6 °C and a T m 2 of 65,2 °C.
  • H10-03-6 was cloned and expressed in Pichia pastoris as described above. Two constructs with stabilising mutations were also cloned and expressed, namely the single point mutation T250V as well as the combinatory mutation T250V K370L. All proteins were purified and prepared for DSC
  • Stabilizing point mutations in wildtype Fc were selected by a method based on the introduction of random mutations in the Fc by using error prone PCR.
  • the gene coding for wildtype Fc was cloned in the yeast display vector pYD1 (Invitrogen, Carlsbad, CA) using the BamHI and Notl restriction sites.
  • a library of randomly mutated Fc-genes was created following etablished protocols for error prone PCR (reviewed e.g. in McCullum EO et al.: Random mutagenesis by error-prone PCR. Methods Mol Biol. 2010; 634:103-9; Cirino PC et al.: Generating mutant libraries using error-prone PCR. Methods Mol Biol.
  • the GeneMorph II Random Mutagenesis Kit (Stratagene, La Jolla, CA) was used in the work decribed here.
  • the PCR primers that were used encompass the 25 bases upstream of the BamHI site and the 25 bases downstream of the Notl site of pYD1 , respectively.
  • primers specific for the Fc insert can also be used.
  • This library was expressed as a yeast surface display library following the method as described by Boder and Wittrup, 1997 (Boder ET, Wittrup KD: Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997 Jun; 15(6):553-7). Growth of the yeast surface display library was overnight at 20°C in SD-CAA-medium (20 g/l glucose, 0.1 M
  • the cells were resuspended in PBS/BSA and the positively staining cells were sorted on a FACS Aria cell sorter (BD, Franklin Lakes, NJ). The sorted cells were subsequently centrifuged. Since the yeast cells did not survive the incubation at 79°C, it was necessary to isolated the DNA from the dead cells, and to use this DNA to prepare a new library in fresh S. cerevisiae cells. DNA was isolated from the selected S. cerevisiae cells by using the Zymoprep Yeast Plasmid Miniprep Kit II (ZYMO RESEARCH, Orange, CA, USA).
  • the DNA preparation was subsequently used as the template for a PCR with the same primers that had been used for error prone PCR.
  • a new library was generated by cloning into pYD1 as described above. This cycle of library generation, induction, incubation at 79 °C, FACS sorting, DNA isolation and preparation of a new library was repeated 4 times.
  • the Fc-genes that had been enriched by this method were sequenced by Sanger Dideoxy DNA sequencing.
  • a number of Fc mutant genes that were enriched were subsequently cloned into the vector pPICZalphaA (Invitrogen, Carlsbad, CA), which is a vector for soluble expression in Pichia pastoris. Mutant Fc proteins were subsequently expressed, purified and characterised as described in the examples above.
  • mutant S400F which involves the same position in the Fc sequence as two of the mutants (S400D and S400R) that were identified by the site directed mutagenesis approach as described in Example 1 .
  • Example 4 Fc library based on a Fc scaffold comprising the Q418L and S424T mutations
  • Fc libraries that are more thermostable and also more tolerant to insertions in the EF loop were constructed as follows:
  • the gene coding for wild-type Fc was cloned in the yeast display vector pYD1
  • the libraries had the following designs and designations:
  • Libraryl residues 419-422 were mutated and in addition, 5 residues were inserted
  • Library2 same as Libraryl , plus introduction of the stabilising mutations Q418L and S424T
  • libraries were prepared in a modified form in which the positions Q418 und S424 were mutated to introduce the stabilizing mutations Q418L and S424T.
  • the libraries were prepared in parallel with the respective wild- type residues at positions 418 and 424.
  • the libraries were analyzed as follows:
  • the libraries were expressed as yeast surface display libraries following the method as described by Boder and Wittrup, 1997 (Boder ET, Wittrup KD: Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997 Jun; 15(6):553-7). Growth of the yeast surface display libraries was overnight at 20°C in SD-CAA-medium (20 g/l glucose, 0.1 M KH2PO4/K2HPO4, pH 6, 10 g/l (NH 4 ) 2 S0 4 ,
  • the cultures were diluted with fresh medium to an OD600 of 1 and after 4 h of incubation the cells were centrifuged and resuspended in SGR-CAA (same as SD-CAA, but 20 g/l galactose and 10 g/l raffinose instead of glucose) to an OD600 of SGR-CAA (same as SD-CAA, but 20 g/l galactose and 10 g/l raffinose instead of glucose) to an OD600 of SGR-CAA (same as SD-CAA, but 20 g/l galactose and 10 g/l raffinose instead of glucose) to an OD600 of SGR-CAA (same as SD-CAA, but 20 g/l galactose and 10 g/l raffinose instead of glucose) to an OD600 of SGR-CAA (same as SD-CAA, but 20 g/l galact
  • Xpress antibody as well as with 2 ⁇ g/ml His-tagged CD64.
  • 2 ⁇ g/ml Streptavidin-APC and 2 ⁇ g/ml Alexa Fluor 488-labeled anti-His antibody were used. All staining steps were performed in PBS/BSA at 4°C for 30 min with gentle shaking. Washing steps were performed with PBS/BSA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne un procédé de préparation d'un mutant Fc d'IgG humaines manipulé pour gagner en stabilité par manipulation d'au moins une des mutations ponctuelles indiquées dans le Tableau 1 ou d'une combinaison de ces mutations ponctuelles, le mutant Fc manipulé pour gagner en stabilité et une banque de Fc comprenant un répertoire desdits mutants Fc manipulés pour gagner en stabilité.
PCT/EP2011/065463 2010-09-07 2011-09-07 Fc humain stabilisé WO2012032080A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175534 2010-09-07
EP10175534.6 2010-09-07

Publications (1)

Publication Number Publication Date
WO2012032080A1 true WO2012032080A1 (fr) 2012-03-15

Family

ID=43013265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/065463 WO2012032080A1 (fr) 2010-09-07 2011-09-07 Fc humain stabilisé

Country Status (1)

Country Link
WO (1) WO2012032080A1 (fr)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144871A1 (fr) 2013-03-15 2014-09-18 The Centre For Drug Research And Development Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
WO2015095953A1 (fr) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Systèmes de liaison contenant un sulfonamide pour conjugués de médicaments
CN104955953A (zh) * 2012-11-27 2015-09-30 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对,其制备方法及用途
WO2016041082A1 (fr) 2014-09-17 2016-03-24 CDRD Ventures, Inc. Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9605061B2 (en) 2010-07-29 2017-03-28 Xencor, Inc. Antibodies with modified isoelectric points
US9650446B2 (en) 2013-01-14 2017-05-16 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US9850320B2 (en) 2014-11-26 2017-12-26 Xencor, Inc. Heterodimeric antibodies to CD3 X CD20
US9856327B2 (en) 2014-11-26 2018-01-02 Xencor, Inc. Heterodimeric antibodies to CD3 X CD123
WO2018052556A1 (fr) * 2016-08-02 2018-03-22 Visterra, Inc. Polypeptides synthétiques et leurs utilisations
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3363818A4 (fr) * 2015-10-12 2019-09-25 Ajou University Industry-Academic Cooperation Foundation Procédé de production d'une paire de mutants hétérodimères du domaine ch3 d'anticorps utilisant l'appariement de levures et paire mutante de ch3 ainsi produite
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2021131021A1 (fr) * 2019-12-27 2021-07-01 中外製薬株式会社 Anticorps anti-ctla-4 et son utilisation
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US11078249B2 (en) 2016-08-10 2021-08-03 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
WO2021232163A1 (fr) * 2020-05-20 2021-11-25 Zymeworks Inc. Variants de région fc d'immunoglobuline comprenant des mutations améliorant la stabilité
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
US11377477B2 (en) 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
WO2022219058A1 (fr) * 2021-04-14 2022-10-20 Anjarium Biosciences Ag Polypeptides dérivés de fc
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
US11591401B2 (en) 2020-08-19 2023-02-28 Xencor, Inc. Anti-CD28 compositions
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11787864B2 (en) 2018-10-23 2023-10-17 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US11932675B2 (en) 2019-10-11 2024-03-19 Genentech, Inc. PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
RU2822498C2 (ru) * 2016-08-02 2024-07-08 Вистерра, Инк. Генно-инженерные полипептиды и их применение

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
WO2004029207A2 (fr) * 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
WO2004035752A2 (fr) 2002-10-15 2004-04-29 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
WO2004063351A2 (fr) 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
WO2006020114A2 (fr) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Regions fc de variants
WO2006053301A2 (fr) 2004-11-12 2006-05-18 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
WO2006076594A2 (fr) 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
WO2006088494A2 (fr) 2004-07-12 2006-08-24 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et methodes d'utilisation de ces anticorps
WO2006105338A2 (fr) 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20070003546A1 (en) 2002-03-01 2007-01-04 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1847602A1 (fr) * 2005-01-12 2007-10-24 Kirin Pharma Kabushiki Kaisha Anticorps igg1 et igg 3 humains stabilises

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
US20070003546A1 (en) 2002-03-01 2007-01-04 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004029207A2 (fr) * 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
WO2004035752A2 (fr) 2002-10-15 2004-04-29 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
WO2004063351A2 (fr) 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
US20050037000A1 (en) 2003-01-09 2005-02-17 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2006088494A2 (fr) 2004-07-12 2006-08-24 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et methodes d'utilisation de ces anticorps
WO2006020114A2 (fr) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Regions fc de variants
WO2006053301A2 (fr) 2004-11-12 2006-05-18 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
WO2006076594A2 (fr) 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
EP1847602A1 (fr) * 2005-01-12 2007-10-24 Kirin Pharma Kabushiki Kaisha Anticorps igg1 et igg 3 humains stabilises
WO2006105338A2 (fr) 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ATWELL S ET AL., J MOL BIOL., vol. 270, no. 1, 4 July 1997 (1997-07-04), pages 26 - 35
ATWELL S ET AL: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.", JOURNAL OF MOLECULAR BIOLOGY 4 JUL 1997 LNKD- PUBMED:9231898, vol. 270, no. 1, 4 July 1997 (1997-07-04), pages 26 - 35, XP002610109, ISSN: 0022-2836 *
BODER ET, WITTRUP KD: "Yeast surface display for screening combinatorial polypeptide libraries", NAT BIOTECHNOL., vol. 15, no. 6, June 1997 (1997-06-01), pages 553 - 7, XP002945515, DOI: doi:10.1038/nbt0697-553
CIRINO PC ET AL.: "Generating mutant libraries using error-prone PCR", METHODS MOL BIOL., vol. 231, 2003, pages 3 - 9
DALL' ACQUA ET AL., BIOCHEMISTRY, vol. 37, no. 26, 1998, pages 9266 - 9273
DALL'ACQUA W ET AL: "Contribution of domain interface residues to the stability of antibody CH3 domain homodimers.", BIOCHEMISTRY 30 JUN 1998 LNKD- PUBMED:9649307, vol. 37, no. 26, 30 June 1998 (1998-06-30), pages 9266 - 9273, XP002610112, ISSN: 0006-2960 *
DEMAREST SJ ET AL., J MOL BIOL., vol. 335, no. 1, 2 January 2004 (2004-01-02), pages 41 - 8
DEMAREST STEPHEN J ET AL: "Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences.", JOURNAL OF MOLECULAR BIOLOGY 2 JAN 2004 LNKD- PUBMED:14659738, vol. 335, no. 1, 2 January 2004 (2004-01-02), pages 41 - 48, XP002610108, ISSN: 0022-2836 *
KIEL, C. ET AL., J MOL BIOL, vol. 348, 2005, pages 759 - 75
KUNKEL TA.: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC NATL ACAD SCI U S A., vol. 82, no. 2, January 1985 (1985-01-01), pages 488 - 92
LEFRANC ET AL.: "IMGT, the international ImMunoGeneTics", NUCLEIC ACIDS RES., vol. 27, 1999, pages 209 - 212
MCCULLUM EO ET AL.: "Random mutagenesis by error-prone PCR", METHODS MOL BIOL., vol. 634, 2010, pages 103 - 9
OGANESYAN VAHEH ET AL., MOLECULAR IMMUNOLOGY, vol. 45, no. 7, 2008, pages 1872 - 1882
OGANESYAN VAHEH ET AL: "Structural characterization of a human Fc fragment engineered for extended serum half-life.", MOLECULAR IMMUNOLOGY MAY 2009 LNKD- PUBMED:19250681, vol. 46, no. 8-9, May 2009 (2009-05-01), pages 1750 - 1755, XP002610111, ISSN: 1872-9142 *
OGANESYAN VAHEH ET AL: "Structural characterization of a human Fc fragment engineered for lack of effector functions.", ACTA CRYSTALLOGRAPHICA. SECTION D, BIOLOGICAL CRYSTALLOGRAPHY JUN 2008 LNKD- PUBMED:18560159, vol. 64, no. Pt 6, June 2008 (2008-06-01), pages 700 - 704, XP002610114, ISSN: 0907-4449 *
OGANESYAN VAHEH ET AL: "Structural characterization of a mutated, ADCC-enhanced human Fc fragment.", MOLECULAR IMMUNOLOGY APR 2008 LNKD- PUBMED:18078997, vol. 45, no. 7, April 2008 (2008-04-01), pages 1872 - 1882, XP002610110, ISSN: 0161-5890 *
OKAZAKI AKIRA ET AL: "Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.", JOURNAL OF MOLECULAR BIOLOGY 5 MAR 2004 LNKD- PUBMED:15037082, vol. 336, no. 5, 5 March 2004 (2004-03-05), pages 1239 - 1249, XP002610113, ISSN: 0022-2836 *
SABOULARD D ET AL., BIOTECHNIQUES, vol. 39, no. 3, September 2005 (2005-09-01), pages 363 - 8
SCHYMKOWITZ, J. W. ET AL., PROC NATL ACAD SCI U S A, vol. 102, 2005, pages 10147 - 52
STAVENHAGEN JB ET AL., ADV ENZYME REGUL., vol. 48, December 2007 (2007-12-01), pages 152 - 64
VIRNEKAS ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 5600 - 5607
WEINER MP, COSTA GL, SCHOETTLIN W, CLINE J, MATHUR E, BAUER JC.: "Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction", GENE, vol. 151, no. 1-2, 30 December 1994 (1994-12-30), pages 119 - 23, XP023541818, DOI: doi:10.1016/0378-1119(94)90641-6
WITTRUP, CURR OPIN BIOTECHNOL, vol. 12, 2001, pages 395 - 399
WOZNIAK-KNOPP ET AL.: "Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties", PROTEIN ENG DES SEL., vol. 23, no. 4, 11 February 2010 (2010-02-11), pages 289 - 97, XP009137665, DOI: doi:10.1093/protein/gzq005
YANEZ ET AL., NUCLEIC ACIDS RES., vol. 32, 2004, pages E158

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9605061B2 (en) 2010-07-29 2017-03-28 Xencor, Inc. Antibodies with modified isoelectric points
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9951145B2 (en) 2012-11-27 2018-04-24 Ajou University Industry—Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
EP3878964A1 (fr) * 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Paire de variants du domaine ch3 induisant la formation d'hétérodimère de région constante de chaîne lourde d'anticorps à haute efficacité, procédé de préparation associé et utilisation associée
US11286311B2 (en) 2012-11-27 2022-03-29 Ajou University Industry-Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
CN104955953B (zh) * 2012-11-27 2019-04-26 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对，其制备方法及用途
CN104955953A (zh) * 2012-11-27 2015-09-30 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对,其制备方法及用途
EP2927321A4 (fr) * 2012-11-27 2016-06-15 Ajou Univ Ind Acad Coop Found Paire de variants du domaine ch3 induisant la formation d'hétérodimère de région constante de chaîne lourde d'anticorps à haute efficacité, procédé de préparation associé, et utilisation associée
US9650446B2 (en) 2013-01-14 2017-05-16 Xencor, Inc. Heterodimeric proteins
US11634506B2 (en) 2013-01-14 2023-04-25 Xencor, Inc. Heterodimeric proteins
US11718667B2 (en) 2013-01-14 2023-08-08 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10472427B2 (en) 2013-01-14 2019-11-12 Xencor, Inc. Heterodimeric proteins
JP7025388B2 (ja) 2013-01-14 2022-02-24 ゼンコア インコーポレイテッド 新規異種二量体タンパク質
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10738133B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
JP2020018318A (ja) * 2013-01-14 2020-02-06 ゼンコア インコーポレイテッド 新規異種二量体タンパク質
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11814423B2 (en) 2013-03-15 2023-11-14 Xencor, Inc. Heterodimeric proteins
WO2014144871A1 (fr) 2013-03-15 2014-09-18 The Centre For Drug Research And Development Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
US10287364B2 (en) 2013-03-15 2019-05-14 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US11299554B2 (en) 2013-03-15 2022-04-12 Xencor, Inc. Heterodimeric proteins
EP3590922A1 (fr) 2013-03-15 2020-01-08 Zymeworks Inc. Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2015095953A1 (fr) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Systèmes de liaison contenant un sulfonamide pour conjugués de médicaments
US11840579B2 (en) 2014-03-28 2023-12-12 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US10858451B2 (en) 2014-03-28 2020-12-08 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
EP4029873A1 (fr) 2014-09-17 2022-07-20 Zymeworks Inc. Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
WO2016041082A1 (fr) 2014-09-17 2016-03-24 CDRD Ventures, Inc. Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
US11111315B2 (en) 2014-11-26 2021-09-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11859011B2 (en) 2014-11-26 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US12129309B2 (en) 2014-11-26 2024-10-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10889653B2 (en) 2014-11-26 2021-01-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10913803B2 (en) 2014-11-26 2021-02-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11225528B2 (en) 2014-11-26 2022-01-18 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11945880B2 (en) 2014-11-26 2024-04-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US11673972B2 (en) 2014-11-26 2023-06-13 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US9856327B2 (en) 2014-11-26 2018-01-02 Xencor, Inc. Heterodimeric antibodies to CD3 X CD123
US11352442B2 (en) 2014-11-26 2022-06-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US9850320B2 (en) 2014-11-26 2017-12-26 Xencor, Inc. Heterodimeric antibodies to CD3 X CD20
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11091548B2 (en) 2015-03-05 2021-08-17 Xencor, Inc. Modulation of T cells with bispecific antibodies and Fc fusions
US11155639B2 (en) 2015-10-12 2021-10-26 Ajou University Industry—Academic Cooperation Foundation Method for producing antibody CH3 domain heterodimeric mutant pair using yeast mating and CH3 mutant pair produced thereby
EP3363818A4 (fr) * 2015-10-12 2019-09-25 Ajou University Industry-Academic Cooperation Foundation Procédé de production d'une paire de mutants hétérodimères du domaine ch3 d'anticorps utilisant l'appariement de levures et paire mutante de ch3 ainsi produite
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US11492407B2 (en) 2016-06-14 2022-11-08 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11236170B2 (en) 2016-06-14 2022-02-01 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11225521B2 (en) 2016-06-28 2022-01-18 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US12054545B2 (en) 2016-06-28 2024-08-06 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
RU2822498C2 (ru) * 2016-08-02 2024-07-08 Вистерра, Инк. Генно-инженерные полипептиды и их применение
WO2018052556A1 (fr) * 2016-08-02 2018-03-22 Visterra, Inc. Polypeptides synthétiques et leurs utilisations
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
US11078249B2 (en) 2016-08-10 2021-08-03 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US11692019B2 (en) 2016-08-10 2023-07-04 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
US11584794B2 (en) 2016-10-14 2023-02-21 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11939384B1 (en) 2018-02-08 2024-03-26 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12129300B2 (en) 2018-02-08 2024-10-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
US11377477B2 (en) 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
US11787864B2 (en) 2018-10-23 2023-10-17 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
US11932675B2 (en) 2019-10-11 2024-03-19 Genentech, Inc. PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
JPWO2021131021A1 (fr) * 2019-12-27 2021-07-01
JP7373588B2 (ja) 2019-12-27 2023-11-02 中外製薬株式会社 抗ｃｔｌａ－４抗体およびその使用
WO2021131021A1 (fr) * 2019-12-27 2021-07-01 中外製薬株式会社 Anticorps anti-ctla-4 et son utilisation
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2021232163A1 (fr) * 2020-05-20 2021-11-25 Zymeworks Inc. Variants de région fc d'immunoglobuline comprenant des mutations améliorant la stabilité
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
US11591401B2 (en) 2020-08-19 2023-02-28 Xencor, Inc. Anti-CD28 compositions
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2022219058A1 (fr) * 2021-04-14 2022-10-20 Anjarium Biosciences Ag Polypeptides dérivés de fc
US12139525B2 (en) 2021-07-02 2024-11-12 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

Similar Documents

Publication Publication Date Title
WO2012032080A1 (fr) Fc humain stabilisé
US9651559B2 (en) Display of binding agents
CA2721614C (fr) Immunoglobuline cytotoxique
EP2046831B1 (fr) Nouvelles immunoglobulines polyvalentes
US20120094874A1 (en) Stabilized immunoglobulin constant domains
EP2407487A1 (fr) Anticorps modulaires multi-spécifiques
EP2546268A1 (fr) Immunoglobuline s'internalisant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11754867

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 07.06.2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11754867

Country of ref document: EP

Kind code of ref document: A1